Patent Assignment
Reel/Frame 024369/0022
Release of Security Interest
Recorded: 2010-05-11
Pages: 10
Assignor
KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.
Executed: 2010-05-11
Assignee
CREDIT SUISSE AG
11 MADISON AVENUE, AS ADMINISTRATIVE AGENT, NEW YORK, NEW YORK, 10010
Covered Properties
(66)
Novel Method of Myocardial Imaging
Patent:
5,070,877 →
Application:
07/330,156 →
Process Improvement in the Synthesis of N-[3-(3-Cyano-Pyrazolo[1,5-a] Pyrimidin-7-Yl)Phenyl]-N-Ethylacetamide
Patent:
5,714,607 →
Application:
08/758,132 →
Thiophenes Useful for Modulating the Adenosine Receptor
Patent:
5,939,432 →
Application:
08/959,758 →
N6-Substituted-Adenosine-5'-Uronamides as Adenosine Receptor Modulator
Patent:
6,048,865 →
Application:
09/124,434 →
Adenosine A3 Receptor Modulators
Patent:
6,448,253 →
Application:
09/154,435 →
Allosteric Adenosine Receptor Modulators
Patent:
6,323,214 →
Application:
09/156,077 →
Pharmaceutical Compositions Based on Dalfopristine and on Quinupristine, and Preparation Thereof
Patent:
6,187,746 →
Application:
09/210,938 →
Allosteric Adenosine Receptor Modulators
Patent:
6,177,444 →
Application:
09/307,225 →
Allosteric Adenosine Receptor Modulators
Patent:
6,194,449 →
Application:
09/307,286 →
Stabilized Pharmaceutical Compositions, with Quinnupristine and Dalfopristine Base and Their Preparation
Patent:
5,994,338 →
Application:
09/314,070 →
The Use of Adenosine A3 Receptor Antagonists to Inhibit Tumor Growth
Patent:
6,326,390 →
Application:
09/377,271 →
Adenosine a Receptor Modulators
Patent:
6,407,236 →
Application:
09/379,300 →
Diagnostic Uses of 2-Substituted Adenosine Carboxamides
Patent:
6,368,573 →
Application:
09/440,330 →
Adenosine, A3 receptor modulators
Patent:
6,358,964 →
Application:
09/625,583 →
Method for treating hyper-excited sensory nerve functions in humans
Patent:
6,248,774 →
Application:
09/654,994 →
Allosteric Adenosine Receptor Modulators
Method for Treating Pain in Humans
Dalfopristine/Quinupristine Combinations with Cefpirome
Method for Increasing the Bioavailability of Metaxalone
Patent:
6,407,128 →
Application:
09/998,206 →
Stabilized Pharmaceutical and Thyroid Hormone Compositions and Method of Preparation
Levothyroxine Compositions and Methods
Patent:
6,555,581 →
Application:
10/077,677 →
Allosteric Adenosine Receptor Modulators
Method for Increasing the Bioavailability of Metaxalone
Pharmaceutically Active Compounds and Methods of Use
Adenosine A3 Receptor Modulators
Methods of Administering Levothyroxine Pharmaceutical Compositions
Synthesis of 2-Aralkoxyadenosines and 2-Alkoxyadenosines
Tyrosyl Derivatives and Their Use as P2X7 Receptor Modulators
8-Heteroaryl Xanthine Adenosine A2B Receptor Antagonists
Pharmaceutically Active Compounds Having a Tricyclic Pyrazolotriazolopyrimidine Ring Structure and Methods of Use
Enhancing treatment of MDR cancer with adenosine A3 antagonists
Application:
10/603,406 →
Publication:
US 2004/0067932
Novel Adenosine A3 Receptor Agonists
Synthesis of 2-Aralkyloxyadenosines, 2-Alkoxyadenosines, and Their Analogs
Adenosine A3 Receptor Modulators
Methods of Modifying the Bioavailability of Metaxalone
Patent:
7,714,006 →
Application:
11/182,661 →
Enhancing treatment of cancer and HIF-1 mediated disorders with adenosine A3 receptor antagonists
Application:
11/286,127 →
Publication:
US 2006/0204502
Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists
Application:
11/286,129 →
Publication:
US 2006/0194756
Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions
Application:
11/317,063 →
Publication:
US 2006/0183804
Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm
Application:
11/332,120 →
Publication:
US 2006/0159621
Methods of diagnosing and prognosticating solid tumors and melanoma
Application:
11/334,332 →
Publication:
US 2007/0037179
Novel Adenosine A3 Receptor Modulators
8-Heteroaryl Xanthine Adenosine A2B Receptor Antagonists
Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
Application:
11/396,420 →
Publication:
US 2006/0246133
Pharmaceutically Active Compounds and Methods of Use
Compositions of stabilized ramipril in combination with another active agent
Application:
11/594,535 →
Publication:
US 2007/0116762
Pharmaceutical compositions for promoting wound healing
Application:
11/729,624 →
Publication:
US 2007/0232561
Adenosine A2B Receptor Agonists
Adenosine A2B Receptor Antagonists
Adenosine A3 Receptor Modulators
Combination Therapy for the Treatment of Pain
Application:
11/872,800 →
Publication:
US 2008/0108603
Combination Therapy for the Treatment of Pain
Application:
11/872,859 →
Publication:
US 2008/0108622
Combination Therapy for the Treatment of Pain
Application:
11/872,878 →
Publication:
US 2008/0113969
Pharmaceutical Compositions for Promoting Wound Healing
Application:
11/873,909 →
Publication:
US 2011/0144027
Allosteric Modulators of the A1 Adenosine Receptor
Allosteric Modulators of the A1 Adenosine Receptor
Pyrrolotriazolopyrimidine Derivatives , Pharmaceutical Compositions Containing Them and Methods of Treating Conditions and Diseases Mediated by the Adenosine A2A Receptor Activity
Adenosine A2A Receptor Antagonists
Pharmaceutical Compositions for the Treatment of Pain
Application:
12/125,511 →
Publication:
US 2009/0041839
CRYSTALS OF (2-AMINO-4,5,6,7-TETRAHYDROBENZO[b]THIEN-3-YL)(4-CHLOROPHENYL)METHANONE
Application:
12/175,711 →
Publication:
US 2009/0023799
Novel Adenosine A3 Receptor Agonists
Application:
12/201,157 →
Publication:
US 2009/0233878
Crystal Forms of 2-[2-(4-Chlorophenyl)Ethoxy]Adenosine
Application:
61/015,229 →
Crystal Forms of 2-{2-[(Cyclohexyl)Methylene]Hydrazino}Adenosine
Application:
61/038,251 →
Allosteric Enhancers of the A1 Adenosine Receptor
Application:
61/051,399 →
Allosteric Enhancers of the A1 Adenosine Receptor
Application:
61/053,793 →
Methods of Treating Atherosclerosis
Application:
61/081,235 →
Methods of Treating Atherosclerosis
Application:
61/081,247 →
Related Assignments
(21)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Oct 4, 2001
From: FEGER, CELINE; MOREILLON, PHILIPPE; VOUILLAMOZ, JACQUES
To: AVENTIS PHARMA S.A.
Reel/Frame 012231/0574 →
Assignment of Assignor's Interest
Nov 28, 2001
From: LEUNG, EDWARD
To: KING PHARMACEUTICALS, INC.
Reel/Frame 012334/0011 →
Assignment of Assignor's Interest
Nov 28, 2001
From: CHEN, SHIH-FENG
To: KING PHARMACEUTICALS, INC.
Reel/Frame 012334/0008 →
Assignment of Assignor's Interest
Jul 7, 2003
From: ELAN PHARMACEUTICALS, INC.
To: JONES PHARMA INCORPORATED
Reel/Frame 014235/0344 →
Assignment of Assignor's Interest
Jul 7, 2003
From: ELAN PHARMACEUTICALS, INC.
To: JONES PHARMA INCORPORATED
Reel/Frame 014237/0019 →
Change of Name
Aug 18, 2003
From: AMERICAN CYANAMID COMPANY
To: WYETH HOLDINGS CORPORATION
Reel/Frame 014373/0673 →
Assignment of Assignor's Interest
Aug 18, 2003
From: WYETH HOLDINGS CORPORATION
To: WYETH
Reel/Frame 014373/0676 →
Assignment of Assignor's Interest
Oct 1, 2003
From: AVENTIS PHARMA S.A.
To: JONES PHARMA INCORPORATED
Reel/Frame 014548/0941 →
Assignment of Assignor's Interest
Oct 1, 2003
From: AVENTIS PHARMA S.A.
To: JONES PHARMA INCORPORATED
Reel/Frame 014546/0355 →
Assignment of Assignor's Interest
Oct 1, 2003
From: AVENTIS PHARMA S.A.
To: JONES PHARMA INCORPORATED
Reel/Frame 014546/0359 →
Assignment of Assignor's Interest
Nov 4, 2003
From: WYETH
To: JONES PHARMA INCORPORATED
Reel/Frame 014662/0049 →
Assignment of Assignor's Interest
Oct 12, 2005
From: BARALDI, PIER GIOVANNI
To: KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC.
Reel/Frame 017073/0432 →
Assignment of Assignor's Interest
Jul 14, 2006
From: BARALDI, PIER GIOVANNI
To: KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC.
Reel/Frame 017947/0075 →
Merger and Change of Name
Mar 6, 2007
From: JONES PHARMA INCORPORATED
To: KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC
Reel/Frame 018961/0829 →
Security Agreement
Dec 30, 2008
From: KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC.
To: CREDIT SUISSE, AS AGENT
Reel/Frame 022034/0870 →
Security Agreement
May 13, 2010
From: KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.
To: CREDIT SUISSE AG
Reel/Frame 025703/0628 →
Release of Security Interest
Feb 3, 2011
From: CREDIT SUISSE AG
To: KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.
Reel/Frame 025741/0564 →
Release of Security Interest
Feb 3, 2011
From: CREDIT SUISSE AG
To: KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.
Reel/Frame 025738/0132 →
Release of Security Interest
Feb 4, 2011
From: CREDIT SUISSE AG
To: KING PHARMACEUTICALS, INC.
Reel/Frame 025746/0793 →
Change Assignee Address and Correspondence Address
Feb 13, 2017
From: KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.
To: KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.
Reel/Frame 041694/0288 →
Assignee and Correspondence Address Change
May 17, 2017
From: KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.
To: KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.
Reel/Frame 042486/0322 →